1
|
Liang X, Shen J. Impact of KRAS mutation status on outcomes of metastatic colorectal cancer treated with anti-angiogenic agents: a meta-analysis. J Chemother 2019; 32:41-48. [PMID: 31838964 DOI: 10.1080/1120009x.2019.1692282] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- Xiaojun Liang
- Department of ICU, Jinshan Hospital Affiliated to Fudan University, Shanghai, China
| | - Jie Shen
- Department of ICU, Jinshan Hospital Affiliated to Fudan University, Shanghai, China
| |
Collapse
|
2
|
Barclay JL, Keshvari S, Whitehead JP, Inder WJ. Development of an enzyme-linked immunosorbent assay for thrombospondin-1 and comparison of human plasma and serum concentrations. Ann Clin Biochem 2016; 53:606-10. [DOI: 10.1177/0004563216628891] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/30/2015] [Indexed: 11/16/2022]
Abstract
Background Thrombospondin-1 (TSP-1) is a circulating matricellular glycoprotein produced from many cell types including platelets. Currently TSP-1 is measured in either plasma or serum, using expensive commercial assays. Aim To develop and validate a cost effective in-house immunoassay for human TSP-1 suitable for quantitating levels from both plasma and serum. Methods An in-house enzyme-linked immunosorbent assay (ELISA) was developed for the measurement of human TSP-1. Sixteen healthy volunteers (8 male and 8 female), mean age 29 years (range 21–49), body mass index (BMI) mean 23.3 kg/m2 (range 17.3–26.7) had non-fasted venous blood sampled at 0800 h and 1600 h for both plasma and serum TSP-1. Results The assay limit of quantitation was 7.8 μg/L, inter assay CV was 17–31%, intra assay CV was 3–4% for plasma and <9% for serum. Plasma TSP-1 ranged from 133 to 478 μg/L (mean concentration 290 μg/L) in normal volunteers. Serum TSP-1 was approximately 100-fold higher, ranging from 13,700 to 44,400 μg/L (mean concentration 257,00 μg/L). There was no correlation between plasma and serum TSP-1. Conclusions TSP-1 can be readily measured in human plasma using ELISA. Serum concentrations are 100-fold higher, reflecting documented TSP-1 release by platelets, and does not provide a meaningful measure of circulating concentrations.
Collapse
Affiliation(s)
- Johanna L Barclay
- Mater Research Institute, University of Queensland, Brisbane, Australia
- Translational Research Institute, Brisbane, Australia
| | - Sahar Keshvari
- Mater Research Institute, University of Queensland, Brisbane, Australia
- Translational Research Institute, Brisbane, Australia
- School of Medicine, the University of Queensland, Brisbane, Australia
| | - Jonathan P Whitehead
- Mater Research Institute, University of Queensland, Brisbane, Australia
- Translational Research Institute, Brisbane, Australia
| | - Warrick J Inder
- Translational Research Institute, Brisbane, Australia
- School of Medicine, the University of Queensland, Brisbane, Australia
- Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Australia
| |
Collapse
|